{"id":10824,"date":"2019-11-29T10:55:45","date_gmt":"2019-11-29T09:55:45","guid":{"rendered":"https:\/\/udic.es\/?p=10824"},"modified":"2019-11-29T10:55:45","modified_gmt":"2019-11-29T09:55:45","slug":"an-innovative-and-surprising-therapy-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/an-innovative-and-surprising-therapy-in-parkinsons-disease\/","title":{"rendered":"An innovative and surprising therapy in Parkinson\u2019s disease"},"content":{"rendered":"
Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.<\/p>\n","protected":false},"excerpt":{"rendered":"
Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.<\/p>\n","protected":false},"author":4,"featured_media":9345,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-10824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-parkinson-en"],"yoast_head":"\n